Andrew Levin, M.D., Ph.D. resigned from the Board of Directors of Vor Biopharma Inc. effective July 6, 2026, stating no disagreement with the company. To fill the vacancy, the Board appointed David Zaccardelli, Pharm.D. effective July 7, 2026. Zaccardelli, a former CEO of Verona Pharma plc and Dova Pharmaceuticals, Inc., will serve as an independent Class II director until the 2029 annual meeting. He will receive a $40,000 annual cash retainer and an initial stock option grant valued at up to $700,000 or 68,000 shares. Vor Biopharma Inc. is a biotechnology company focused on developing therapies for cancer.

At its Annual Meeting of Stockholders held on June 11, 2026, Vor Biopharma Inc. stockholders approved an amendment and restatement of the 2021 Equity Incentive Plan. The Amended 2021 Plan modifies the Evergreen Provision to calculate the annual 4% share reserve increase based on the sum of issued and outstanding common stock plus shares issuable upon exercise of pre-funded warrants. Additionally, the plan now provides for full vesting of unvested time-based awards upon an employee's death. Stockholders also elected Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. as Class II Directors and ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year. Vor Biopharma Inc. is a biotechnology company.

On June 8, 2026, Vor Biopharma Inc. announced that RemeGen Co., Ltd. received conditional approval from the NMPA for telitacicept for the treatment of adult patients with IgA nephropathy and approval from the NMPA for telitacicept for the treatment of adult patients with Sjögren’s disease in China.